slc1a1 Protein

slc1a1 Protein

Introduction

Slc1A1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-protein"> [@proper2000]

| Attribute | Value | [@arnold2008]
|-----------|-------|
| Protein Name | Sodium/Glutamate Transporter 1 |
| Gene Symbol | SLC1A1 |
| UniProt ID | [P43005](https://www.uniprot.org/uniprot/P43005) |
| NCBI Gene ID | [6507](https://www.ncbi.nlm.nih.gov/gene/6507) |
| Protein Family | SLC1 family (EAAT) |
| Molecular Weight | ~57 kDa |
| Subcellular Location | Plasma membrane |
| Expression | Brain, kidney, intestine |

</div>}

Overview

SLC1A1 (Sodium/Glutamate Transporter 1), also known as EAAT3 (Excitatory Amino Acid Transporter 3), is a high-affinity glutamate transporter responsible for clearing excitatory neurotransmitters from the synaptic cleft. This protein plays crucial roles in preventing excitotoxicity and maintaining glutamate homeostasis in the brain.

Molecular Function

Transport Mechanism

Sodium coupling - 3 Na+ ions per glutamate

Proton coupling - 1 H+ cotransport

Counter-transport - 1 K+ counter-transport

Electrogenic - Net positive charge transport

Substrate Specificity

• Glutamate - Primary substrate
• Aspartate - Alternative substrate
• Cystine - In exchange for glutamate (system Xc-)

Disease Associations

Neurological Disorders

Epilepsy

...

slc1a1 Protein

Introduction

Slc1A1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-protein"> [@proper2000]

| Attribute | Value | [@arnold2008]
|-----------|-------|
| Protein Name | Sodium/Glutamate Transporter 1 |
| Gene Symbol | SLC1A1 |
| UniProt ID | [P43005](https://www.uniprot.org/uniprot/P43005) |
| NCBI Gene ID | [6507](https://www.ncbi.nlm.nih.gov/gene/6507) |
| Protein Family | SLC1 family (EAAT) |
| Molecular Weight | ~57 kDa |
| Subcellular Location | Plasma membrane |
| Expression | Brain, kidney, intestine |

</div>}

Overview

SLC1A1 (Sodium/Glutamate Transporter 1), also known as EAAT3 (Excitatory Amino Acid Transporter 3), is a high-affinity glutamate transporter responsible for clearing excitatory neurotransmitters from the synaptic cleft. This protein plays crucial roles in preventing excitotoxicity and maintaining glutamate homeostasis in the brain.

Molecular Function

Transport Mechanism

Sodium coupling - 3 Na+ ions per glutamate

Proton coupling - 1 H+ cotransport

Counter-transport - 1 K+ counter-transport

Electrogenic - Net positive charge transport

Substrate Specificity

• Glutamate - Primary substrate
• Aspartate - Alternative substrate
• Cystine - In exchange for glutamate (system Xc-)

Disease Associations

Neurological Disorders

Epilepsy

• Glutamate clearance - Impaired in epileptic tissue
• Excitotoxicity - Contributes to seizure progression
• Therapeutic targeting - Modulators under investigation

Alzheimer's Disease

• Excitotoxicity - Glutamate-induced neuronal damage
• Synaptic function - Altered glutamate recycling
• Therapeutic implications - Glutamate modulators

Parkinson's Disease

• Dopaminergic [neurons](/entities/neurons) - Vulnerable to excitotoxicity
• Metabolic stress - Impaired glutamate transport
• Neuroprotection - EAAT3 enhancement

Obsessive-Compulsive Disorder

• Genetic association - SLC1A1 variants linked to OCD
• Cortico-striatal circuits - Glutamate dysregulation
• Therapeutic implications - Glutamate-targeting drugs

Therapeutic Targeting

Drug Development

• Glutamate transport enhancers - Increase EAAT3 activity
• Allosteric modulators - Target transporter conformation
• Gene therapy - AAV-mediated expression

Research Directions

• Biomarkers - SLC1A1 as disease marker
• Neuroimaging - PET ligands for EAATs
• Combination therapy - With antioxidants

Key Publications

• PMID: 7502583(https://pubmed.ncbi.nlm.nih.gov/7502583/) - EAAT3 cloning and characterization
• PMID: 10559285(https://pubmed.ncbi.nlm.nih.gov/10559285/) - EAAT3 in epilepsy
• PMID: 18515852(https://pubmed.ncbi.nlm.nih.gov/18515852/) - SLC1A1 and OCD

Therapeutic Implications

Drug Development Targets

SLC1A3 (EAAT1) represents a promising therapeutic target for multiple neurological conditions. The transporter's role in glutamate homeostasis makes it an attractive target for modulating excitotoxicity.

| Approach | Mechanism | Disease | Status |
|----------|-----------|---------||
| EAAT1 agonists | Increase uptake | Epilepsy | Preclinical |
| EAAT1 modulators | Allosteric modulation | Migraine | Research |
| Gene therapy | Increase expression | AD | Experimental |

Blood-Brain Barrier Considerations

Transport across the [BBB](/entities/blood-brain-barrier) remains a challenge for EAAT1-targeted drugs. Novel delivery approaches include:

• Receptor-mediated transcytosis
• Nanoparticle delivery systems
• Intranasal administration

Research Directions

Biomarker Potential

EAAT1 expression patterns may serve as biomarkers for:

• Glial activation in neuroinflammation
• Disease progression in MS
• Treatment response in epilepsy

Genetic Variants

Several SNPs in SLC1A3 have been associated with:

• Migraine susceptibility
• Epilepsy risk
• ALS progression

Background

The study of Slc1A1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• [Glutamate Transporters](/entities/glutamate)
• [Excitotoxicity](/mechanisms/excitotoxicity-neurodegeneration)
• [SLC1A1 Gene](/genes/slc1a1)

External Links

• [UniProt P43005](https://www.uniprot.org/uniprot/P43005)
• [NCBI Gene SLC1A1](https://www.ncbi.nlm.nih.gov/gene/6507)

References

[Kanai Y, Hediger MA, Primary structure and functional characterization of a high-affinity glutamate transporter (1992)](https://pubmed.ncbi.nlm.nih.gov/7502583/)

[Proper EA, Oestreicher AB, Jansen GH, et al, Immunohistochemical characterization of excitatory amino acid transporters in the human hippocampus (2000)](https://pubmed.ncbi.nlm.nih.gov/10559285/)

[Arnold PD, Sicard T, Burroughs E, et al, Glutamate system genes associated with OCD (2008)](https://pubmed.ncbi.nlm.nih.gov/18515852/)